Guidance Issued on Use of Direct Oral Anticoagulants in Obese

This article originally appeared here.
Share this content:
Guidance Issued on Use of Direct Oral Anticoagulants in Obese
Guidance Issued on Use of Direct Oral Anticoagulants in Obese

MONDAY, April 11, 2016 (HealthDay News) -- Recommendations have been issued for the use of direct oral anticoagulants (DOACs) in obese patients; the guideline was published online March 22 in the Journal of Thrombosis and Haemostasis.

Karlyn Martin, M.D., from the University of North Carolina at Chapel Hill, and colleagues reviewed the literature and developed guidance for clinicians relating to the use of DOACs in obese patients.

The authors recommend appropriate standard dosing of DOACs in patients with a body mass index (BMI) up to 40 kg/m² and weight of 120 kg for treatment and prevention of venous thromboembolism, and for prevention of ischemic stroke and systemic arterial embolism in non-valvular atrial fibrillation. Due to limited clinical data for patients at the extreme of weight, use of DOACs is not recommended for patients with BMI >40 kg/m² or weight >120 kg; pharmacokinetic/pharmacodynamic evidence suggests decreased drug exposure, reduced peak concentration, and shorter half-lives with increasing weight. A drug-specific peak and trough level should be checked if DOACs are used for patients with BMI >40 kg/m² or weight >120 kg; continuation of DOAC seems reasonable if the level falls within the expected range.

"As for all cases, our statements may provide guidance but do not replace clinical judgment for the management of individual patients," the authors write.

Several authors disclosed financial ties to the pharmaceutical industry.

Abstract
Full Text

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Incident Contrast Sensitivity Common in Middle-Aged Adults

Incident Contrast Sensitivity Common in Middle-Aged Adults

Factors linked to elevated risk include cadmium level in highest quintile, older age, more plaque sites

Tafamidis Treats Transthyretin Amyloid Cardiomyopathy

Tafamidis Treats Transthyretin Amyloid Cardiomyopathy

Reduces all-cause mortality, cardiovascular-related hospitalizations compared with placebo

Scribes Improve Physician Workflow, Patient Interaction

Scribes Improve Physician Workflow, Patient Interaction

Scribes lower EHR documentation burden for doctors and increase time spent interacting with patients

is free, fast, and customized just for you!




Already a member?

Sign In Now »